Jiang Zheng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Jiang Zheng has a total of 69 co-authors. Here are the top co-authors by number of shared publications:
Shuijie Shen
Center for Developmental Therapeutics, Seattle Children's Research Institute, Division of Gastroenterology and Hepatology, Department of Pediatrics, University of Washington , Seattle, Washington 98195, United States
9 shared publications- Ying Peng
Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang, China
7 shared publications Dan Lu
College of Pharmacy, Shenyang Pharmaceutical University, Shenyang, Liaoning 110016, PR China
4 shared publicationsFan Zhang
4 shared publicationsJiaojiao Cao
College of Pharmacy, Shenyang Pharmaceutical University, Shenyang, Liaoning 110016, PR China
4 shared publicationsLin Ji
College of Pharmacy, Shenyang Pharmaceutical University, Shenyang, Liaoning 110016, PR China
4 shared publications
Latest Publications
- 26 January 2016
- Published by American Chemical Society (ACS) in Chemical Research in Toxicology
- Vol. 29 (2) , 180-189
9-Glutathionyl-6,7-dihydro-1-hydroxymethyl-5H-pyrrolizine Is the Major Pyrrolic Glutathione Conjugate of Retronecine-Type Pyrrolizidine Alkaloids in Liver Microsomes and in Rats
Retronecine-, otonecine-, and heliotridine-type pyrrolizidine alkaloids (PAs) are all reported to be hepatotoxic. These PAs are suggested to be metabolized to the corresponding electrophilic dehydropyrrolizidine alkaloids (dehydro-PAs) and subsequently conjugated with macromolecules, such as glutathione (GSH). In the present study, a total of five glutathione conjugates, named M1–M5, were detected in rat and human liver microsomal incubations with three retrornecine-type PAs (isoline, retrorsine, or monocrotaline) in the presence of glutathione, and were chemically synthesized. M1 and M3 were unambiguously identified as a pair of epimers of 7-glutathionyl-6,7-dihydro-1-hydroxymethyl-5H-pyrrolizine (7-GSH-DHP), and M4 and M5 were epimers of 7,9-diglutathionyl-6,7-dihydro-1-hydroxymethyl-5H-pyrrolizine (7,9-diGSH-DHP). M2, an extremely unstable conjugate, was proposed to be 9-glutathionyl-6,7-dihydro-1-hydroxymethyl-5H-pyrrolizine (9-GSH-DHP). It was the most abundant among the five GSH conjugates, and the finding corrects the mistake that 7-GSH-DHP is the predominant GSH conjugate derived from dehydro-PAs. Similar patterns in glutathione conjugate profile were observed in the bile of rats treated with the PAs. This is the first study to describe 9-GSH-DHP as a major pyrrolic GSH conjugate of retronecine-type PAs, providing insight into the interactions of dehydro-PAs with biomolecules.
- 26 January 2016
- Published by American Chemical Society (ACS) in Chemical Research in Toxicology
- Vol. 29 (2) , 180-189
9-Glutathionyl-6,7-dihydro-1-hydroxymethyl-5H-pyrrolizine Is the Major Pyrrolic Glutathione Conjugate of Retronecine-Type Pyrrolizidine Alkaloids in Liver Microsomes and in Rats
Retronecine-, otonecine-, and heliotridine-type pyrrolizidine alkaloids (PAs) are all reported to be hepatotoxic. These PAs are suggested to be metabolized to the corresponding electrophilic dehydropyrrolizidine alkaloids (dehydro-PAs) and subsequently conjugated with macromolecules, such as glutathione (GSH). In the present study, a total of five glutathione conjugates, named M1–M5, were detected in rat and human liver microsomal incubations with three retrornecine-type PAs (isoline, retrorsine, or monocrotaline) in the presence of glutathione, and were chemically synthesized. M1 and M3 were unambiguously identified as a pair of epimers of 7-glutathionyl-6,7-dihydro-1-hydroxymethyl-5H-pyrrolizine (7-GSH-DHP), and M4 and M5 were epimers of 7,9-diglutathionyl-6,7-dihydro-1-hydroxymethyl-5H-pyrrolizine (7,9-diGSH-DHP). M2, an extremely unstable conjugate, was proposed to be 9-glutathionyl-6,7-dihydro-1-hydroxymethyl-5H-pyrrolizine (9-GSH-DHP). It was the most abundant among the five GSH conjugates, and the finding corrects the mistake that 7-GSH-DHP is the predominant GSH conjugate derived from dehydro-PAs. Similar patterns in glutathione conjugate profile were observed in the bile of rats treated with the PAs. This is the first study to describe 9-GSH-DHP as a major pyrrolic GSH conjugate of retronecine-type PAs, providing insight into the interactions of dehydro-PAs with biomolecules.
- Open Access
- 8 October 2015
- Published by Wiley in British Journal of Pharmacology
- Vol. 173 (1) , 212-221
Homoharringtonine binds to and increases myosin‐9 in myeloid leukaemia
Background and Purpose: Homoharringtonine (HHT) is a natural alkaloid isolated from various Cephalotaxus species. HHT has been used to treat acute myeloid leukaemia (AML), chronic myeloid leukaemia (CML), chronic lymphocyte leukaemia and myelodysplastic syndromes. Although HHT inhibits protein synthesis and promotes apoptosis of leukaemia cells in preclinical studies, its molecular target proteins remain unknown. The aim of this study was to identify target proteins of HHT.Experimental Approach: We have synthesized a biotinylated affinity column and used it to identify targets of HHT and confirmed the results by MS and Western blots. We also examined the effects of HHT on the target protein and determined roles of the target protein in anti‐leukaemia activities of HHT through Western blots, flow cytometry and retrovirus transfection.Key Results: Myosin‐9, a member of the myosin super‐family, was identified as a direct interactor of HHT. Furthermore, HHT up‐regulated the expression level of myosin‐9 in both AML and CML cell lines in a time‐dependent manner. Thus, HHT‐induced apoptosis of leukaemia cells begins in 6 h and continues to increase for 24 h. There is a positive correlation between up‐regulated myosin‐9 expression level and increased percentage of apoptotic cells mediated by HHT. Overexpression of myosin‐9 could increase the sensitivity of the leukaemia cells to the cytotoxicity of HHT and arrest cells in S and G2/M phases.Conclusions and Implications: Our results indicated that myosin‐9 was the target protein of HHT and played an important role in the HHT‐induced apoptosis of leukaemia cells.
- 8 October 2015
- Published by Wiley in British Journal of Pharmacology
- Vol. 173 (1) , 212-221
Open AccessHomoharringtonine binds to and increases myosin‐9 in myeloid leukaemia
Background and Purpose: Homoharringtonine (HHT) is a natural alkaloid isolated from various Cephalotaxus species. HHT has been used to treat acute myeloid leukaemia (AML), chronic myeloid leukaemia (CML), chronic lymphocyte leukaemia and myelodysplastic syndromes. Although HHT inhibits protein synthesis and promotes apoptosis of leukaemia cells in preclinical studies, its molecular target proteins remain unknown. The aim of this study was to identify target proteins of HHT.Experimental Approach: We have synthesized a biotinylated affinity column and used it to identify targets of HHT and confirmed the results by MS and Western blots. We also examined the effects of HHT on the target protein and determined roles of the target protein in anti‐leukaemia activities of HHT through Western blots, flow cytometry and retrovirus transfection.Key Results: Myosin‐9, a member of the myosin super‐family, was identified as a direct interactor of HHT. Furthermore, HHT up‐regulated the expression level of myosin‐9 in both AML and CML cell lines in a time‐dependent manner. Thus, HHT‐induced apoptosis of leukaemia cells begins in 6 h and continues to increase for 24 h. There is a positive correlation between up‐regulated myosin‐9 expression level and increased percentage of apoptotic cells mediated by HHT. Overexpression of myosin‐9 could increase the sensitivity of the leukaemia cells to the cytotoxicity of HHT and arrest cells in S and G2/M phases.Conclusions and Implications: Our results indicated that myosin‐9 was the target protein of HHT and played an important role in the HHT‐induced apoptosis of leukaemia cells.
- 1 October 2015
- Published by Elsevier in Analytica Chimica Acta
- Vol. 896, 93-101
Detection of cysteine- and lysine-based protein adductions by reactive metabolites of 2,5-dimethylfuran
- 1 October 2015
- Published by Elsevier in Analytica Chimica Acta
- Vol. 896, 93-101
Detection of cysteine- and lysine-based protein adductions by reactive metabolites of 2,5-dimethylfuran
- 1 October 2015
- Published by Elsevier in Chemico-Biological Interactions
- Vol. 240, 346-352
Psoralen, a mechanism-based inactivator of CYP2B6
- 1 October 2015
- Published by Elsevier in Chemico-Biological Interactions
- Vol. 240, 346-352
Psoralen, a mechanism-based inactivator of CYP2B6
- 1 October 2015
- Published by Elsevier in Drug Metabolism and Disposition
- Vol. 43 (10) , 1491-1498
In Vitro and In Vivo Characterization of Reactive Intermediates of Corynoline
Corynoline is a 1,3-benzodioxole-containing isoquinoline alkaloid isolated from Corydalis bugeana Turcz., a traditional herbal medicine. Corynoline has reportedly demonstrated multiple pharmacologic properties. Previous studies have also shown that corynoline induced cytotoxicity and inhibited cytochrome P450 enzymes, but the mechanisms of the adverse effects remain unknown. The major objective of the present study was to identify reactive metabolites of corynoline responsible for the cytotoxicity and enzyme inhibition. Three oxidative metabolites (M1-M3) were detected by LC-MS/MS in rat liver microsomal incubations after exposure to corynoline. M1 and M2 were two isomers of catechol derivatives, and M3 was a di-catechol. M1-M3 were also observed in urine of rats given corynoline. A total of four N-acetylcysteine (NAC) conjugates (M4-M7) were detected in microsomes containing corynoline, NAC, and NADPH. Apparently, M4 and M5 were derived from M1, M6 resulted from M2, and M7 was a M3-derived NAC conjugate. This indicates that corynoline was bioactivated to ortho-quinone derivatives. No corynoline-derived NAC conjugates (M4-M7) were detected in urine of rats given corynoline, but three corresponding cysteinylglycine (Cys-Gly) conjugates (M8-M10) were observed instead. Recombinant P450 enzyme incubations demonstrated that CYPs 2C9, 3A4, and 2C19 were mainly involved in metabolic activation of corynoline. The metabolism study facilitates the understanding of corynoline-induced cytotoxicity and P450 enzyme inhibition.
- 1 October 2015
- Published by Elsevier in Drug Metabolism and Disposition
- Vol. 43 (10) , 1491-1498
In Vitro and In Vivo Characterization of Reactive Intermediates of Corynoline
Corynoline is a 1,3-benzodioxole-containing isoquinoline alkaloid isolated from Corydalis bugeana Turcz., a traditional herbal medicine. Corynoline has reportedly demonstrated multiple pharmacologic properties. Previous studies have also shown that corynoline induced cytotoxicity and inhibited cytochrome P450 enzymes, but the mechanisms of the adverse effects remain unknown. The major objective of the present study was to identify reactive metabolites of corynoline responsible for the cytotoxicity and enzyme inhibition. Three oxidative metabolites (M1-M3) were detected by LC-MS/MS in rat liver microsomal incubations after exposure to corynoline. M1 and M2 were two isomers of catechol derivatives, and M3 was a di-catechol. M1-M3 were also observed in urine of rats given corynoline. A total of four N-acetylcysteine (NAC) conjugates (M4-M7) were detected in microsomes containing corynoline, NAC, and NADPH. Apparently, M4 and M5 were derived from M1, M6 resulted from M2, and M7 was a M3-derived NAC conjugate. This indicates that corynoline was bioactivated to ortho-quinone derivatives. No corynoline-derived NAC conjugates (M4-M7) were detected in urine of rats given corynoline, but three corresponding cysteinylglycine (Cys-Gly) conjugates (M8-M10) were observed instead. Recombinant P450 enzyme incubations demonstrated that CYPs 2C9, 3A4, and 2C19 were mainly involved in metabolic activation of corynoline. The metabolism study facilitates the understanding of corynoline-induced cytotoxicity and P450 enzyme inhibition.
- 25 August 2015
- Published by Springer Nature in Archives of Toxicology
- Vol. 90 (7) , 1737-1748
CYP3A5 mediates bioactivation and cytotoxicity of tetrandrine
Tetrandrine is a diaryl ether-type bisbenzylisoquinoline alkaloid and has shown multiple pharmacological activities. Our early work demonstrated that tetrandrine produced acute pulmonary toxicity and that tetrandrine was biotransformed to a quinone methide-derived metabolite mediated by CYP3A enzymes. The formation of the reactive intermediate is suggested to be responsible for the pulmonary toxicity induced by tetrandrine. In the present study, a WI-38-based Cyp3a5 transgenic cell line (WI-38/Cyp3a5) was established to investigate the role of CYP3A5 in tetrandrine-induced cytotoxicity. The transgenic cells were found to be more susceptible to the cytotoxicity of tetrandrine than the wild-type cells (WI-38/Vector). WI-38/Cyp3a5 cells showed higher cellular ROS levels, higher LDH activities in culture media, but lower cellular GSH contents than those observed in WI-38/Vector cells after exposure to tetrandrine. And severer apoptosis were observed in WI-38/Cyp3a5 cells after treatment with tetrandrine: WI-38/Cyp3a5 cells had higher proportion of early and late apoptotic cells, higher expression levels of caspase-3, but lower level of Bcl-2 than WI-38/Vector cells. This study provided strong evidence that CYP3A5 participated in tetrandrine-induced cytotoxicity.
- 25 August 2015
- Published by Springer Nature in Archives of Toxicology
- Vol. 90 (7) , 1737-1748
CYP3A5 mediates bioactivation and cytotoxicity of tetrandrine
Tetrandrine is a diaryl ether-type bisbenzylisoquinoline alkaloid and has shown multiple pharmacological activities. Our early work demonstrated that tetrandrine produced acute pulmonary toxicity and that tetrandrine was biotransformed to a quinone methide-derived metabolite mediated by CYP3A enzymes. The formation of the reactive intermediate is suggested to be responsible for the pulmonary toxicity induced by tetrandrine. In the present study, a WI-38-based Cyp3a5 transgenic cell line (WI-38/Cyp3a5) was established to investigate the role of CYP3A5 in tetrandrine-induced cytotoxicity. The transgenic cells were found to be more susceptible to the cytotoxicity of tetrandrine than the wild-type cells (WI-38/Vector). WI-38/Cyp3a5 cells showed higher cellular ROS levels, higher LDH activities in culture media, but lower cellular GSH contents than those observed in WI-38/Vector cells after exposure to tetrandrine. And severer apoptosis were observed in WI-38/Cyp3a5 cells after treatment with tetrandrine: WI-38/Cyp3a5 cells had higher proportion of early and late apoptotic cells, higher expression levels of caspase-3, but lower level of Bcl-2 than WI-38/Vector cells. This study provided strong evidence that CYP3A5 participated in tetrandrine-induced cytotoxicity.
- 6 August 2015
- Published by Taylor & Francis in Xenobiotica
- Vol. 46 (4) , 335-341
Mechanism-based inactivation of cytochrome P450 2B6 by isopsoralen
1. Isopsoralen (IPRN) is a major component in many traditional medicinal herbs widely used in Asian countries. The objective of the present study was to investigate the inhibitory effect of IPRN on cytochrome P450 2B6 (CYP2B6) and the mechanism involved in the enzyme inactivation. 2. Pre-incubation of CYP2B6 with IPRN resulted in a time- and concentration-dependent enzyme activity loss. The values of KI and kinact were found to be 7.89 μM and 0.067 min−1, respectively. Ticlopidine exhibited protective effect on the IPRN-induced enzyme inactivation. The estimated partition ratio of the inactivation was 122. The GSH trapping experiments indicate that an epoxide and/or γ-ketoenal intermediate were/was generated in IPRN-fortified microsomal incubations. The synthetic work verified the formation of the reactive intermediate(s). Additionally, CYPs2E1, 2C19, 2B6 and 1A2 were found to be the major enzymes participating in the bioactivation of IPRN. 3. IPRN was characterized as a mechanism-based inactivator of CYP2B6. An IPRN-derived furanoepoxide and/or γ-ketoenal intermediate(s) were/was generated and may be responsible for the inactivation of CYP2B6.
- 6 August 2015
- Published by Taylor & Francis in Xenobiotica
- Vol. 46 (4) , 335-341
Mechanism-based inactivation of cytochrome P450 2B6 by isopsoralen
1. Isopsoralen (IPRN) is a major component in many traditional medicinal herbs widely used in Asian countries. The objective of the present study was to investigate the inhibitory effect of IPRN on cytochrome P450 2B6 (CYP2B6) and the mechanism involved in the enzyme inactivation. 2. Pre-incubation of CYP2B6 with IPRN resulted in a time- and concentration-dependent enzyme activity loss. The values of KI and kinact were found to be 7.89 μM and 0.067 min−1, respectively. Ticlopidine exhibited protective effect on the IPRN-induced enzyme inactivation. The estimated partition ratio of the inactivation was 122. The GSH trapping experiments indicate that an epoxide and/or γ-ketoenal intermediate were/was generated in IPRN-fortified microsomal incubations. The synthetic work verified the formation of the reactive intermediate(s). Additionally, CYPs2E1, 2C19, 2B6 and 1A2 were found to be the major enzymes participating in the bioactivation of IPRN. 3. IPRN was characterized as a mechanism-based inactivator of CYP2B6. An IPRN-derived furanoepoxide and/or γ-ketoenal intermediate(s) were/was generated and may be responsible for the inactivation of CYP2B6.
- 15 April 2015
- Published by Wiley in Rapid Communications in Mass Spectrometry
- Vol. 29 (7) , 681-689
Mass spectrometry based detection of glutathione with sensitivity for single‐cell analysis
Rationale: Glutathione (GSH) is a very important molecule that participates in various physiologically important events. Depletion of cellular GSH has been suggested as a biomarker of early stage of cell injury. Assessment of GSH with high selectivity and sensitivity is in demand in many fields of life sciences. Methods: Cell lysates were deproteinated by 5‐sulfosalicylic acid. Glutathione was derivatized with monobromobimane to form a GSH conjugate. S ‐Hexylglutathione was employed as internal standard. The resulting samples were analyzed using a high‐performance liquid chromatography/electrospray ionization tandem mass spectrometry (HPLC/ESI‐MS/MS) system. Results: The limit of detection was as low as 500 amol with high selectivity. The approach was sensitive enough to detect GSH content in a single human erythrocyte. The technique is the most sensitive approach among the reported MS‐based GSH assays. Conclusions: A monobromobimane derivatization and mass spectrometry based method was developed for the assessment of GSH. The derivatized GSH was chemically stable against autooxidation. With the great selectivity and sensitivity, the approach is anticipated to serve as a routine method for assessment of GSH and possibly other important endogenous low molecular weight thiols. Copyright © 2015 John Wiley & Sons, Ltd.
- 15 April 2015
- Published by Wiley in Rapid Communications in Mass Spectrometry
- Vol. 29 (7) , 681-689
Mass spectrometry based detection of glutathione with sensitivity for single‐cell analysis
Rationale: Glutathione (GSH) is a very important molecule that participates in various physiologically important events. Depletion of cellular GSH has been suggested as a biomarker of early stage of cell injury. Assessment of GSH with high selectivity and sensitivity is in demand in many fields of life sciences. Methods: Cell lysates were deproteinated by 5‐sulfosalicylic acid. Glutathione was derivatized with monobromobimane to form a GSH conjugate. S ‐Hexylglutathione was employed as internal standard. The resulting samples were analyzed using a high‐performance liquid chromatography/electrospray ionization tandem mass spectrometry (HPLC/ESI‐MS/MS) system. Results: The limit of detection was as low as 500 amol with high selectivity. The approach was sensitive enough to detect GSH content in a single human erythrocyte. The technique is the most sensitive approach among the reported MS‐based GSH assays. Conclusions: A monobromobimane derivatization and mass spectrometry based method was developed for the assessment of GSH. The derivatized GSH was chemically stable against autooxidation. With the great selectivity and sensitivity, the approach is anticipated to serve as a routine method for assessment of GSH and possibly other important endogenous low molecular weight thiols. Copyright © 2015 John Wiley & Sons, Ltd.
- 8 April 2015
- Published by Springer Nature in Archives of Toxicology
- Vol. 90 (4) , 863-872
Metabolic activation of furan moiety makes Diosbulbin B hepatotoxic
Diosbulbin B (DIOB), a furanoid, is a major constituent of herbal medicine Dioscorea bulbifera L. Exposure to DIOB caused liver injury in humans and experimental animals. The mechanisms of DIOB-induced hepatotoxicities remain unknown. The present study demonstrated that DIOB induced hepatotoxicities in a time- and dose-dependent manner in mice. H&E stained histopathologic image showed the occurrence of necrosis in the liver obtained from the mice treated with DIOB at dose of 200 mg/kg. Pretreatment with KTC protected the animals from hepatotoxicities and hepatic GSH depletion induced by DIOB, increased area under the concentration–time curve of blood DIOB, decreased urinary excretion of GSH conjugates derived from DIOB, and increased urinary excretion of parent drug. Pretreatment with BSO exacerbated DIOB-induced hepatotoxicities. In order to define the role of furan moiety in DIOB-induced liver toxicities, we replaced the furan of DIOB with a tetrahydrofuran group by chemical hydrogenation of the furan ring of DIOB. No liver injury was observed in the animals given the same doses of tetrahydro-DIOB. The furan moiety was essential for DIOB-induced hepatotoxicities. The results implicate the cis-enedial reactive metabolite of DIOB was responsible for the observed toxicities. The observed modest depletion of hepatic GSH in DIOB-treated animals suggests the actions of one or more reactive metabolites, and the hepatic injury observed could be due at least in part to reactions of these metabolites with crucial biomolecules. Cytochrome P450 3A enzymes are implicated in DIOB-induced hepatotoxicities by catalyzing the formation of the reactive metabolite of DIOB.
- 8 April 2015
- Published by Springer Nature in Archives of Toxicology
- Vol. 90 (4) , 863-872
Metabolic activation of furan moiety makes Diosbulbin B hepatotoxic
Diosbulbin B (DIOB), a furanoid, is a major constituent of herbal medicine Dioscorea bulbifera L. Exposure to DIOB caused liver injury in humans and experimental animals. The mechanisms of DIOB-induced hepatotoxicities remain unknown. The present study demonstrated that DIOB induced hepatotoxicities in a time- and dose-dependent manner in mice. H&E stained histopathologic image showed the occurrence of necrosis in the liver obtained from the mice treated with DIOB at dose of 200 mg/kg. Pretreatment with KTC protected the animals from hepatotoxicities and hepatic GSH depletion induced by DIOB, increased area under the concentration–time curve of blood DIOB, decreased urinary excretion of GSH conjugates derived from DIOB, and increased urinary excretion of parent drug. Pretreatment with BSO exacerbated DIOB-induced hepatotoxicities. In order to define the role of furan moiety in DIOB-induced liver toxicities, we replaced the furan of DIOB with a tetrahydrofuran group by chemical hydrogenation of the furan ring of DIOB. No liver injury was observed in the animals given the same doses of tetrahydro-DIOB. The furan moiety was essential for DIOB-induced hepatotoxicities. The results implicate the cis-enedial reactive metabolite of DIOB was responsible for the observed toxicities. The observed modest depletion of hepatic GSH in DIOB-treated animals suggests the actions of one or more reactive metabolites, and the hepatic injury observed could be due at least in part to reactions of these metabolites with crucial biomolecules. Cytochrome P450 3A enzymes are implicated in DIOB-induced hepatotoxicities by catalyzing the formation of the reactive metabolite of DIOB.
- 1 January 2015
- Published by Elsevier in Chemico-Biological Interactions
- Vol. 226, 23-29
Mechanism-based inactivation of cytochrome P450 2B6 by isoimperatorin
- 1 January 2015
- Published by Elsevier in Chemico-Biological Interactions
- Vol. 226, 23-29
Mechanism-based inactivation of cytochrome P450 2B6 by isoimperatorin